<DOC>
	<DOC>NCT00237133</DOC>
	<brief_summary>Open-label Phase IV trial of Letrozole 2,5mg po/day for 120 days prior to surgery for patients with locally advanced breast in postmenopausal women expressing hormonal receptors ( ER and PR)</brief_summary>
	<brief_title>Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1. Postmenopausal women 2. Primary locally invasive breast cancer 3. Histological confirmed by core needle biopsy, whose tumors are estrogen (ER) and / or progesterone (PgR) positive, defined by core biopsy immunohistochemistry with &gt; 10% positive malignant epithelial cells. 4. Post menopausal status 5. Tumor measurable by clinical examination, mammography and ultrasound 1. Prior treatment with letrozole or tamoxifen. 2. Patients with bilateral breast tumors 3. Patients who are eligible for breast conserving surgery 4. Evidence of inflammatory breast cancer or distant metastasis. 5. Other concurrent malignant disease 6. Concomitant anticancer treatments such as chemotherapy Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Breast cancer,</keyword>
	<keyword>Letrozole,</keyword>
	<keyword>Hormonal receptors</keyword>
</DOC>